Cargando…

Combination chemoimmunotherapy with monthly cycles of 5-fluorouracil + interferon-alfa-2b in previously-treated advanced cancer

Detalles Bibliográficos
Autores principales:	Quan, Walter, Khemka, Vivek, Martell, Laura S, Pierog, Marci J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991249/ http://dx.doi.org/10.1186/2051-1426-1-S1-P85

Ejemplares similares

Effectiveness of pegylated interferon alfa plus HAART in HIV/HBV treatment-naïve coinfected patients
por: Mata-Marín, JA, et al.
Publicado: (2010)

Unleashing the power of anti-tumor CD4+ T cells: novel insights into the curative mechanisms of chemoimmunotherapy for cancer
por: Habtetsion, Tsadik G, et al.
Publicado: (2015)

Increasing microcirculation after drotrecogin alfa (activated)
por: Donati, A, et al.
Publicado: (2007)

Retrospective observational outcomes for drotrecogin alfa (activated)
por: Cameron, C, et al.
Publicado: (2007)

Use of national guidelines for the introduction of Drotrecogin alfa (activated)
por: Mackenzie, S, et al.
Publicado: (2004)

Extended drotrecogin alfa (activated) therapy in patients with persistent requirement for vasopressor support after 96-hour infusion with commercial drotrecogin alfa (activated)
por: Dhainaut, J, et al.
Publicado: (2008)

Interferon-induced gene expression in systemic lupus erythematosus reflects previous exposure to interferon alpha and is associated with increased disease activity and autoreactivity against RNA-binding proteins
por: Kirou, KA, et al.
Publicado: (2004)

Drotrecogin alfa: start early, ensure response, stop early!
por: Jog, S, et al.
Publicado: (2008)

Interferon (IFNγ) induces cell cycle arrest in RCC cell lines
por: Tate, David J, et al.
Publicado: (2013)

Drotrecogin alfa (activated): a single-centre experience of 110 patients
por: Fletcher, S, et al.
Publicado: (2010)

Drotrecogin alfa (activated) does not impair platelet receptor expression in vitro
por: Schuerholz, T, et al.
Publicado: (2004)

TNF-alfa blockers- promising therapy for chronic uveitis in very young children
por: Tauber, T, et al.
Publicado: (2008)

Multicentre audit of the use of drotrecogin alfa (activated) in UK critical care units
por: Rowan, K, et al.
Publicado: (2007)

A large, single-centre UK registry of drotrecogin alfa-activated use
por: Macchiavello, L, et al.
Publicado: (2007)

Severe sepsis and drotrecogin alfa (activated) use: results from the PROGRESS registry
por: Beale, R, et al.
Publicado: (2007)

Eligibility for drotrecogin alfa therapy on the basis of APACHE II score and organ failure
por: Shulman, R, et al.
Publicado: (2005)

Food choice and phytoestrogen consumption in women previously treated for postmenopausal breast cancer
por: Parry, BM, et al.
Publicado: (2008)

Cardiovascular magnetic resonance assessment in previously repaired ALCAPA
por: Secinaro, Aurelio, et al.
Publicado: (2011)

Audit of adherence to National Institute of Clinical Excellence guidelines for the use of drotrecogin alfa (activated)
por: Vedantham, R, et al.
Publicado: (2007)

Neuroaxial catheters following abdominal surgery and their impact on the use of Drotrecogin alfa (activated) in sepsis
por: Steel, A, et al.
Publicado: (2004)

Drotrecogin alfa in sepsis: analysis of outcomes in a UK district general intensive care unit
por: Pathak, H, et al.
Publicado: (2004)

Outcomes and incidence of bleeding events associated with drotrecogin alfa: a single-centre experience of 440 patients
por: Boyle, A, et al.
Publicado: (2010)

Abatacept for severe anti-TNF-alfa refractory JIA-associated uveitis: one year follow-up
por: Alpigiani, MG, et al.
Publicado: (2011)

Drotrecogin alfa in patients with severe sepsis: experience from a tertiary care center in North India
por: Chawla, R, et al.
Publicado: (2007)

Testing of anti-activated protein C antibodies in four drotrecogin alfa (activated) severe sepsis studies
por: Yan, S, et al.
Publicado: (2008)

Evaluation of immune response profiles of individuals with chronic Hepatitis C treated with interferon alpha and ribavirin, in the foundation of tropical medicine of Amazonas
por: Araújo, Ana Ruth, et al.
Publicado: (2010)

Efficacy, Safety, and Pharmacokinetics of Beroctocog Alfa in Patients Previously Treated for Hemophilia A
por: Hyun, Shin Young, et al.
Publicado: (2015)

Safety of drotrecogin alfa (activated) treatment in patients with severe sepsis on renal replacement therapy without additional anticoagulation
por: Mirea, L, et al.
Publicado: (2011)

Neuro-biological inferences into the depressive disorders of patients with chronic hepatitis C treated with interferon and ribavirin
por: Hurezeanu, Dan, et al.
Publicado: (2014)

P1169: COMPARISON OF REAL-WORLD CLINICAL OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA TREATED WITH EPCORITAMAB VS CHEMOIMMUNOTHERAPY
por: Ip, Andrew, et al.
Publicado: (2023)

A detailed characterization of peripheral blood lymphocytes in patients with myeloproliferative disease treated with pegylated-interferon alpha
por: Kovacsovics-Bankowski, Magdalena, et al.
Publicado: (2015)

B cell depletion by Rituximab severely reduces immunoglobulin levels in patients with ANCA-associated vasculitis previously treated with cyclophosphamide
por: Thiel, Jens, et al.
Publicado: (2011)

Treatment of hemicrania continua by non-invasive vagus nerve stimulation in 2 patients previously treated with occipital nerve stimulation
por: Nesbitt, A, et al.
Publicado: (2013)

Enzyme replacement therapy with taliglucerase alfa: 36‐month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase
por: Pastores, Gregory M., et al.
Publicado: (2016)

Three years experience with drotrecogin alfa (activated) protein C in severe sepsis and septic shock at Salmaniya Medical Complex, Bahrain
por: Mohamed, H, et al.
Publicado: (2007)

Safety and disease response to MEDI-551, an anti-CD19 antibody, in chronic lymphocytic leukemia patients previously treated with rituximab
por: Forero, Andres, et al.
Publicado: (2013)

Canadian ENHANCE data support the efficacy and safety of drotrecogin alfa (activated) despite higher disease severity than the global ENHANCE population
por: Hall, R, et al.
Publicado: (2005)

Efficacy of early administration of thrombomodulin alfa in patients with sepsis-induced disseminated intravascular coagulation: subanalysis from post-marketing surveillance data
por: Eguchi, Y, et al.
Publicado: (2014)

Early prognostic score for neurological outcome at 6 months after cardiac arrest treated with hypothermia
por: Graziani, E, et al.
Publicado: (2015)

Updated efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in metastatic melanoma patients previously treated with anti-PD-1 therapy
por: Prithviraj, Prashanth, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_d73t2cc5g8jl2apif629r8v7ut